Incannex Healthcare Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IXHL research report →
Price Chart
About the company
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA).
- CEO
- Joel Bradley Latham
- IPO
- 2022
- Employees
- 12
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on IXHL
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $43.31M
- P/E
- -1.62
- PEG
- -0.12
- P/S
- 650.17
- P/B
- 0.59
- EV/EBITDA
- 0.58
- Div Yield
- 0.00%
- Gross Margin
- -192.70%
- Op Margin
- -52287.74%
- Net Margin
- -74972.98%
- ROE
- -92.47%
- ROIC
- -44.41%
Latest fiscal year · YoY change
- Revenue
- $86.00K+616.7%
- Gross Profit
- $-160,000-1433.3%
- Op Income
- $-23,789,000
- Net Income
- $-46,885,000-154.0%
- EPS
- $-40.80-1093.0%
- OCF Growth
- +21.0%
- FCF Growth
- +22.3%
- 52W High
- $27.69
- 52W Low
- $2.49
- 50D MA
- $3.34
- 200D MA
- $6.28
- Beta
- 2.73
- RSI (14)
- 69
- Avg Volume
- 209.67K
No earnings-call transcripts are available for IXHL yet.
- Free Float
- 82.5%
- Shares Outstanding
- 11.96M
- Float Shares
- 9.87M
of shares held by institutions
27 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Iron Horse Wealth Management, LLC | 100 | ▲ 100 |
Held by 1 ETFs
Biggest fund positions in IXHL by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 14, 25 | Valentine Troy | other | 11,302,608 |
| Nov 14, 25 | Clark Robert | other | 1,686,956 |
| Nov 14, 25 | Widdows Peter | other | 1,686,956 |
| Nov 14, 25 | Swan Joseph | other | 869,565 |
| Nov 14, 25 | Latham Joel | other | 22,608,692 |
| Nov 14, 25 | Anastassov George | other | 1,686,956 |
| Oct 23, 24 | Barbato Luigi M. | other | 100,476 |
| Oct 21, 24 | Barbato Luigi M. | other | 0 |
| Jun 30, 24 | Swan Joseph | other | 0 |
| Dec 21, 23 | Valentine Troy | other | 670,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IXHL coverage
Recent articles, reports, and earnings notes.
No research on IXHL yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IXHL report →Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea
globenewswire.com · Jul 23
Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea
globenewswire.com · Jun 25
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
globenewswire.com · Jun 10
Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility
globenewswire.com · Jun 10
Incannex Announces Initiation of Research Coverage by Alliance Global Partners
globenewswire.com · Jun 9
Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea
globenewswire.com · May 14
Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development
globenewswire.com · May 12
Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough
globenewswire.com · May 7
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.